FDA Accepts BridgeBio's NDA for Encaleret, Sets May 2027 PDUFA Date
BBIO sits 96% above its 52-week low of $42.09 on light trading volume (0.4× avg).
Summary
The FDA accepted BridgeBio's NDA for encaleret in ADH1, assigning a PDUFA date of May 8, 2027. No advisory committee is planned, which may signal a straightforward review. Encaleret would be the first approved therapy for ADH1, targeting a diagnosed U.S. population of over 2,100 and growing. This follows the NDA submission in May 2026 and positive Phase 3 data. BridgeBio is also expanding the program into pediatric ADH1 and chronic hypoparathyroidism, broadening the potential market. The $1B financing in July provides ample runway to launch.
At the time of this announcement, BBIO was trading at $82.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2B. The 52-week trading range was $42.09 to $93.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.